SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis
Project Number5R01CA124940-02
Contact PI/Project LeaderAGAZIE, YEHENEW M
Awardee OrganizationWEST VIRGINIA UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by applicant): The Src homology phosphotyrosine phosphatase 2 (SHP2) promotes cell proliferation and survival signals induced by receptor Tyr kinases. More specifically, SHP2 is a requisite for EGFR and HER2 signaling pathways, receptors commonly dysregulated in breast and other cancers. In addition to the Ras-ERK and PI3K-Akt signaling pathways, SHP2 transduces ?-catenin signaling downstream of the EGFR and HER2. Therefore, SHP2 acts as a mediator and integrator of these pathways, which are generally regarded as separate. Moreover, our preliminary studies show that SHP2 is overexpressed in breast tumors, suggesting that its increased expression might enhance tumor growth. However, how SHP2 positively modulates the EGFR/HER2 and the ?-catenin signaling pathways is poorly understood. Thus, this research proposal addresses the under-explored, but important area in cancer. The central hypothesis is that SHP2-mediated synergy between the EGFR/HER2 and ?-catenin signaling pathways underlies the mechanism of SHP2 in promoting epithelial-to-mesenchymal transition (EMT) and cell transformation, leading to breast tumor development. This hypothesis is based on the following findings: i) SHP2 is a positive effector of mitogenic and cell survival signals, traits dysregulated in a cancer cell, ii) SHP2 integrates ?-catenin signaling with Ras and PI3K pathways, and iii) it is overexpressed in breast cancer. The specific aims of this proposal are: 1) to explore the extent of SHP2 overexpression in breast cancer and elucidate the mechanism of action of SHP2 in HER2 signaling and transformation, 2) to study the molecular mechanism for EGFR/HER2-induced and SHP2-mediated ?-catenin activation and 3) to investigate the importance of SHP2 in HER2-induced tumorigenesis in vivo. SHP2 protein overexpression in primary breast tumors will be investigated by immunohistochemistry and immunofluorescence. The mechanism of action of SHP2 in HER2 and ?-catenin signaling will be investigated by site-directed mutagenesis, expression in appropriate cells and determining the effect of these expressions on signaling, cell growth and transformation. Finally, the importance of SHP2 in HER2-induced tumorigenesis will be studied in HER2 transgenic and SHP2 knockout (specifically in the mammary gland) mice.
Public Health Relevance Statement
Data not available.
NIH Spending Category
Breast CancerCancer**
Project Terms
AddressAreaBreastCCL4 geneCell NucleusCell ProliferationCell SurvivalCellsDevelopmentERBB2 geneEpidermal Growth Factor ReceptorFoundationsFutureGenesImmunofluorescence ImmunologicImmunohistochemistryIntervention StudiesKnock-outKnockout MiceMalignant NeoplasmsMammary NeoplasmsMammary TumorigenesisMammary glandMediatingMediator of activation proteinMolecularMusNeoplasm MetastasisPathway interactionsPhosphorylation SitePhosphotransferasesProductionProtein DephosphorylationProtein OverexpressionProtein Tyrosine PhosphataseResearch ProposalsSignal PathwaySignal TransductionSite-Directed MutagenesisTestingTherapeutic InterventionTissuesTransgenic OrganismsWorkbasebeta catenincancer cellcell growthcell transformationepithelial to mesenchymal transitiongain of functionin vivoloss of functionmalignant breast neoplasmmutantprognosticreceptorresearch studytraittumortumor growthtumorigenesis
No Sub Projects information available for 5R01CA124940-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA124940-02
Patents
No Patents information available for 5R01CA124940-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA124940-02
Clinical Studies
No Clinical Studies information available for 5R01CA124940-02
News and More
Related News Releases
No news release information available for 5R01CA124940-02
History
No Historical information available for 5R01CA124940-02
Similar Projects
No Similar Projects information available for 5R01CA124940-02